Background Osteosarcoma is characterized by a high malignant and metastatic potential. CCL5 (previously called RANTES) was originally recognized as a product of activated T cells, and plays a crucial role in the migration and metastasis of human cancer cells. It has been reported that the effect of CCL5 is mediated via CCR receptors. However, the effect of CCL5 on migration activity and integrin expression in human osteosarcoma cells is mostly unknown. Methodology/Principal Findings Here we found that CCL5 increased the migration and expression of αvβ3 integrin in human osteosarcoma cells. Stimulation of cells with CCL5 increased CCR5 but not CCR1 and CCR3 expression. CCR5 mAb, inhibitor, and siRNA reduced the CCL5-enhanced the migration and integrin up-regulation of osteosarcoma cells. Activations of MEK, ERK, and NF-κB pathways after CCL5 treatment were demonstrated, and CCL5-induced expression of integrin and migration activity was inhibited by the specific inhibitor and mutant of MEK, ERK, and NF-κB cascades. In addition, over-expression of CCL5 shRNA inhibited the migratory ability and integrin expression in osteosarcoma cells. Conclusions/Significance CCL5 and CCR5 interaction acts through MEK, ERK, which in turn activates NF-κB, resulting in the activations of αvβ3 integrin and contributing the migration of human osteosarcoma cells.
References
[1]
Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, et al. (1988) A human T cell-specific molecule is a member of a new gene family. J Immunol 141: 1018–1025.
[2]
Schall TJ, Bacon K, Toy KJ, Goeddel DV (1990) Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347: 669–671.
[3]
Roth SJ, Carr MW, Springer TA (1995) C-C chemokines, but not the C-X-C chemokines interleukin-8 and interferon-gamma inducible protein-10, stimulate transendothelial chemotaxis of T lymphocytes. Eur J Immunol 25: 3482–3488.
[4]
de la Rosa G, Longo N, Rodriguez-Fernandez JL, Puig-Kroger A, Pineda A, et al. (2003) Migration of human blood dendritic cells across endothelial cell monolayers: adhesion molecules and chemokines involved in subset-specific transmigration. J Leukoc Biol 73: 639–649.
[5]
McCormack G, Moriarty D, O'Donoghue DP, McCormick PA, Sheahan K, et al. (2001) Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res 50: 491–495.
[6]
Ben-Baruch A (2006) Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16: 38–52.
[7]
Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, et al. (1999) Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 59: 4681–4687.
[8]
Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, et al. (2001) Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 7: 285–289.
[9]
Yaal-Hahoshen N, Shina S, Leider-Trejo L, Barnea I, Shabtai EL, et al. (2006) The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res 12: 4474–4480.
[10]
Ek ET, Choong PF (2006) The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas. Expert Rev Anticancer Ther 6: 225–237.
[11]
Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, et al. (2005) Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23: 559–568.
[12]
Arndt CA, Crist WM (1999) Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 341: 342–352.
[13]
Bacci G, Ferrari S, Longhi A, Perin S, Forni C, et al. (2001) Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer 37: 32–38.
[14]
Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127: 679–695.
[15]
Woodhouse EC, Chuaqui RF, Liotta LA (1997) General mechanisms of metastasis. Cancer 80: 1529–1537.
[16]
Humphries MJ (2000) Integrin structure. Biochem Soc Trans 28: 311–339.
[17]
Stupack DG (2007) The biology of integrins. Oncology (Williston Park) 21: 6–12.
[18]
White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, et al. (2004) Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6: 159–170.
[19]
Heyder C, Gloria-Maercker E, Hatzmann W, Niggemann B, Zanker KS, et al. (2005) Role of the beta1-integrin subunit in the adhesion, extravasation and migration of T24 human bladder carcinoma cells. Clin Exp Metastasis 22: 99–106.
[20]
Seales EC, Jurado GA, Brunson BA, Wakefield JK, Frost AR, et al. (2005) Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res 65: 4645–4652.
[21]
Takenaka K, Shibuya M, Takeda Y, Hibino S, Gemma A, et al. (2000) Altered expression and function of beta1 integrins in a highly metastatic human lung adenocarcinoma cell line. Int J Oncol 17: 1187–1194.
[22]
Chuang JY, Yang WH, Chen HT, Huang CY, Tan TW, et al. (2009) CCL5/CCR5 axis promotes the motility of human oral cancer cells. J Cell Physiol 220: 418–426.
[23]
Huang CY, Fong YC, Lee CY, Chen MY, Tsai HC, et al. (2009) CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. Biochem Pharmacol 77: 794–803.
[24]
Yeh WL, Lu DY, Lee MJ, Fu WM (2009) Leptin induces migration and invasion of glioma cells through MMP-13 production. Glia 57: 454–464.
[25]
Chen JH, Huang SM, Chen CC, Tsai CF, Yeh WL, et al. (2011) Ghrelin induces cell migration through GHS-R, CaMKII, AMPK, and NF-kappaB signaling pathway in glioma cells. Journal of cellular biochemistry 112: 2931–2941.
[26]
Huang HC, Shi GY, Jiang SJ, Shi CS, Wu CM, et al. (2003) Thrombomodulin-mediated cell adhesion: involvement of its lectin-like domain. The Journal of biological chemistry 278: 46750–46759.
[27]
Tseng CP, Huang CL, Huang CH, Cheng JC, Stern A, et al. (2003) Disabled-2 small interfering RNA modulates cellular adhesive function and MAPK activity during megakaryocytic differentiation of K562 cells. FEBS letters 541: 21–27.
[28]
Hsieh MT, Hsieh CL, Lin LW, Wu CR, Huang GS (2003) Differential gene expression of scopolamine-treated rat hippocampus-application of cDNA microarray technology. Life sciences 73: 1007–1016.
[29]
Wang YC, Lee PJ, Shih CM, Chen HY, Lee CC, et al. (2003) Damage formation and repair efficiency in the p53 gene of cell lines and blood lymphocytes assayed by multiplex long quantitative polymerase chain reaction. Analytical biochemistry 319: 206–215.
[30]
Kulbe H, Levinson NR, Balkwill F, Wilson JL (2004) The chemokine network in cancer–much more than directing cell movement. Int J Dev Biol 48: 489–496.
[31]
Huang CY, Lee CY, Chen MY, Yang WH, Chen YH, et al. (2009) Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-kappaB-dependent pathways. Journal of cellular physiology 221: 204–212.
[32]
Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, et al. (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85: 683–693.
[33]
Grant S (2008) Cotargeting survival signaling pathways in cancer. J Clin Invest 118: 3003–3006.
[34]
Madrid LV, Mayo MW, Reuther JY, Baldwin AS Jr (2001) Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 276: 18934–18940.
[35]
Martin L, Blanpain C, Garnier P, Wittamer V, Parmentier M, et al. (2001) Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry 40: 6303–6318.
[36]
Shattil SJ, Kim C, Ginsberg MH (2010) The final steps of integrin activation: the end game. Nature reviews Molecular cell biology 11: 288–300.
[37]
Tyner JW, Uchida O, Kajiwara N, Kim EY, Patel AC, et al. (2005) CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nature medicine 11: 1180–1187.
[38]
Sliva D (2004) Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Current cancer drug targets 4: 327–336.
